MOXIFLOXACIN 400MG/100ML INFUSION

BRAND NAME = MEPORVA I.V 
COMPOSITION = MOXIFLOXACIN 400MG/ 100ML INFUSION 
PACKING = 400MG/100ML 


MOXIFLOXACIN EXHIBITS RAPID ACTION WITH LEAST POTENTIAL FOR RESISTANCE THE BACTERICIDAL ACTION OF MOXIFLOXACIN RESULTS  FROM INHIBITION OF THE TOPOISOMERASE II ( DNA GYRASE)  AND TOPOISOMERASE IV REQUIRED FOR BACTERIAL DNA REPLICATION, TRANSCRIPTION, REPAIR , AND RECOMBINATION. 

SEQUENTIAL INTRAVENOUS (IV) COMPARED WITH SEQUENTIAL I.V.  WITH CLARITHROMYCIN IN PATIENTS WITH CAP REQUIRING INITIAL PARENTERAL TREATMENT

UNIQUE FEATURE 
1 BOARD SPECTRUM 
2 SAFE 
3 LEAST CHANCE FOR RESISTANCE 
4 IDEAL ANTIBIOTIC 
5 HIGH POTENCY 
6 LOW INCIDENCE OF SIDE EFFECTS 


INDICATION 
MONOTHERAPY WITH MOXIFLOXACIN IS SUPERIOR TO A . COMBINATION THERAPY OF BETA -LACTAM / BETA- LACTAMASE INHIBITORS + MACROLIDES.

ACUTE BACTERIAL SINUSITIS 
UNCOMPLICATED INFECTION OF SKIN & SUBCUTANEOUS TISSUE 
COMPLICATED INFECTION DISEASES OF ABDOMEN 
COMPLICATED INFECTION OF SKIN & SUBCUTANEOUS TISSUE